PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2016 September 13; 7(37): 59070–59086.
Published online 2016 July 28. doi:  10.18632/oncotarget.10887
PMCID: PMC5312296

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma

Abstract

Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mechanisms of sunitinib resistance in RCC cells is still ambiguous. The microRNA (miRNA) expression signature of patients with sunitinib failure in RCC was constructed using a polymerase chain reaction (PCR)-based array. Several miRNAs that were aberrantly expressed in RCC tissues from patients treated with sunitinib were identified in this analysis. MicroRNA-101 (miR- 101) was markedly suppressed in sunitinib treated RCC tissues. Restoration of miR-101 significantly inhibited cell migration and invasion in Caki-1 and 786-O cells. Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) was directly suppressed by miR-101 in RCC cells, and overexpression of UHRF1 was confirmed in sunitinib-treated RCC tissues. The pathways of nucleotide excision repair and mismatch repair were significantly suppressed by knockdown of UHRF1. Our findings showed that antitumor miR-101- mediated UHRF1 pathways may be suppressed by sunitinib treatment.

Keywords: microRNA, renal cell carcinoma, sunitinib, miR-101, UHRF1

INTRODUCTION

Renal cell carcinoma (RCC) accounts for over 80% of kidney cancers, and 338,000 new cases were diagnosed worldwide in 2012 [1]. The incidence of RCC is increasing due to recent improvements in screening technologies, such as ultrasound and computed tomography. Although molecular-targeted anti-angiogenic multi-tyrosine kinase inhibitors have been developed, they show limited effects, particularly in patients with advanced RCC; consequently, the prognosis of advanced-stage RCC is still poor [2].

Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. A phase 3 clinical trial of sunitinib versus interferon alpha in patients with metastatic RCC ushered in the molecular-targeted era in the treatment of RCC [3]. Although side effects, such as hand-foot syndrome, thrombocytopenia, general fatigue, and hypothyroidism, often occur with sunitinib treatment, sunitinib is still a standard treatment for metastatic RCC due to the relatively longer progression-free survival time and higher response rate [46]. Additionally, sunitinib therapy is often associated with treatment failure in patients with metastatic RCC.

MicroRNAs (miRNAs) are small noncoding RNAs that function as a fine tuner of protein-coding or noncoding gene expression [7, 8]. A growing body of evidence suggests that aberrantly expressed miRNAs contribute to cancer pathogenesis and drug resistance [9, 10]. We have sequentially identified antitumor miRNA-mediated RCC pathways based on RCC miRNA signatures [1113]. The next challenge in our RCC study is to identify key molecules and novel pathways involved in the resistance of molecular-targeted therapies for RCC.

Accordingly, in this study, we constructed a miRNA expression signature to identify pathways activated by sunitinib treatment using autopsy specimens from patients with RCC. The miRNA expression signature revealed that microRNA-101(miR-101) was significantly suppressed in sunitinib-treated RCC tissues compared with that in primary RCC tissues. Additionally, we demonstrated that miR-101 exhibited antitumor activity and directly suppressed ubiquitin-like with PHD and ring finger domains 1 (UHRF1). Moreover, we investigated UHRF1-mediated downstream pathways in RCC cells. Elucidation of the miRNA signature of sunitinib-treated RCC tissues may be useful for identification of the novel molecular mechanisms of RCC recurrence, metastasis, and drug resistance.

RESULTS

Construction of the miRNA expression signature of sunitinib-treated RCC

First, we analyzed the expression levels of mature miRNAs in sunitinib-treated RCC specimens by PCR- based array analysis. Also, we reviewed our miRNA expression data of 10 sunitinib-naïve RCC specimens and 5 normal kidney tissues, and we constructed a signature of downregulated miRNAs in sunitinib-naïve RCC tissues (Supplementary Table S1). Of the 11 sunitinib- treated RCC specimens examined in this study, we used 4 specimens (No. 1, No. 5, No. 6, and No. 8; Table Table1)1) for array analysis. Compared with our previous miRNA signature in primary RCC specimens, 232 miRNAs were significantly downregulated in sunitinib-treated RCC specimens [11]. We listed the top 40 downregulated miRNAs in sunitinib-treated RCC specimens (Table (Table2).2). Among them, we focused on miR-101, which showed the most dramatic downregulation in sunitinib-treated RCC, for further studies.

Table 1
Patient characteristics (sunitinib-treated RCC specimens)
Table 2
Downregulated miRNAs in sunitinib-treated RCC (versus primary RCC)

Expression levels of miR-101 in RCC clinical specimens and RCC cell lines

Using RT-qPCR, we evaluated the expression levels of miR-101 in normal kidney (n = 41), primary RCC (n = 42), and sunitinib-treated RCC (n = 11) tissues. Normal kidney tissues were adjacent to primary RCC tissues. The histological type of all primary RCC specimens was clear cell RCC, and 81.0% of patient tissues were classified as pT1 tumors according to the TNM classification (Table (Table33).

Table 3
Patient characteristics (primary RCC specimens)

The expression levels of miR-101 were significantly downregulated (P = 0.022) in primary RCC tissues compared with that in normal kidney tissues (Figure (Figure1A).1A). Furthermore, the levels of miR-101 were significantly downregulated (P = 0.0013) in sunitinib-treated RCC tissues compared with those in normal kidney tissues (Figure (Figure1A).1A). miR-101 expression levels were low in the RCC cell lines 786-O and Caki-1.

Figure 1
Analysis of miR-101 expression in RCC clinical specimens and functional analysis of miR-101 transfection in 786-O and Caki-1 cells

Effects of restoring miR-101 expression on cell proliferation, migration, and invasion in RCC cells

To investigate the functional roles of miR-101 in RCC, we performed gain-of-function studies in 786-O and Caki-1 cells by transfecting the cells with miRNA mimics.

XTT assays indicated that cell proliferation was inhibited by miR-101 transfection in 786-O cells but not in Caki-1 cells (P < 0.0001; Figure Figure1B).1B). Using wound-healing assays, miR-101 transfection significantly inhibited cell migration as compared with mock- or miR-control-transfected cells (P < 0.0001; Figure Figure1C).1C). Similarly, Matrigel invasion assays demonstrated that cell invasion activity was significantly inhibited in miR-101 transfectants in comparison with mock or miR-control transfectants (P < 0.0001; Figure Figure1D1D).

Identification of target genes suppressed by miR- 101 in RCC

To identify target genes of miR-101, we performed in silico analysis with the TargetScan program and GEO database. Analysis by the TargetScan program demonstrated that miR-101 could target 3,013 genes according to the sequences of their 3′UTRs. Among these genes, 790 had broadly conserved miR-101 sites across vertebrates. To gain further insights into which genes were suppressed by tumour-suppressive miR-101 in RCC, we investigated their expression statuses in RCC clinical specimens and examined gene expression profiles in the GEO database (accession numbers: GSE36985 and GSE22541) to evaluate upregulated genes in RCC specimens. Consequently, among the 790 putative conserved target genes of miR-101, 43 genes were significantly upregulated in RCC specimens compared with those in normal kidney tissues (log2 ratio > 1.0). We sorted these candidate genes in order of expression levels in RCC from the GEO database, because genes with high expression in RCC tissues are thought to function as oncogenes in RCC. Among genes which have conserved target sites for miR-101, UHRF1 was the most upregulated gene. Among genes with multiple conserved target sites for miR-101, EZH2 showed the greatest upregulation (Table (Table44).

Table 4
Putative target genes of miR-101 and upregulated genes in RCC clinical specimens

Thus, we focused on UHRF1 and EZH2 for further studies. Our strategy for selection of miR-101-targeted genes is shown in Figure Figure22.

Figure 2
Selection strategy for target genes of miR-101.

UHRF1 and EZH2 were downregulated by miR- 101 transfection in RCC cells

Next, we performed real-time RT-qPCR in 786- O and Caki-1 cells to analyze whether restoration of miR- 101 altered the expression levels of the UHRF1 and EZH2 genes. Additionally, western blotting was carried out to investigate the effects of miR-101 transfection on UHRF1 and EZH2 protein. The mRNA and protein expression levels of UHRF1 and EZH2 were significantly downregulated by miR-101 transfection as compared with those in mock- or miR-control-transfected cells (P < 0.002 and P < 0.005; Figure Figure3A3A and and3B,3B, Figure Figure4A4A and and4B).4B). Because direct regulation of EZH2 by miR-101 in RCC has been reported by several groups [14, 15], we focused on the UHRF1 gene in this study.

Figure 3
miR-101 directly downregulated UHRF1 expression in RCC cells
Figure 4
Effects of miR-101 transfection on EZH2 mRNA and protein expression in RCC cells

miR-101 directly suppressed UHRF1 in RCC cells

We performed luciferase reporter assays in 786- O cells to determine whether UHRF1 was directly suppressed by miR-101. The TargetScan database predicted that the putative miR-101 target site in UHRF1 was position 1030–1036 in the 3′UTR. We used two vectors: a vector encoding a partial wild-type sequence of the 3′ UTR of UHRF1 mRNA including the predicted miR-101 target site, and a vector lacking the miR-101 target site. We found that the luminescence intensity was significantly reduced by cotransfection with miR-101 and the vector carrying the wild-type 3′UTR of UHRF1. However, the luminescence intensity was not decreased when the seed sequence of the target site was deleted from the vectors (P < 0.0001; Figure Figure3C3C).

Knockdown of UHRF1 significantly inhibited cell proliferation, migration, and invasion in RCC cell lines

To investigate the functional role of UHRF1 in RCC, we carried out loss-of-function studies by siRNA transfection. First, we evaluated the knockdown efficiency of si-UHRF1 transfection in 786-O and Caki- 1 cells. RT-qPCR and western blotting indicated that si- UHRF1 transfection effectively downregulated UHRF1 and UHRF1 in 786-O and Caki-1 cells (P < 0.0001; Figure Figure5A5A and and5B5B).

Figure 5
Effects of UHRF1 knockdown in RCC cells and impact of UHRF1 expression on clinical RCC specimens

In functional assays, si-UHRF1 transfection significantly inhibited cell proliferation compared with that in mock- or si-control-transfected 786-O and Caki- 1 cells. Furthermore, cell migration and invasion were significantly inhibited by si-UHRF1 transfection compared with mock- or si-control-transfection in 786-O and Caki-1 cells (P < 0.0001; Figure 5C–5E).

Identification of pathways suppressed by UHRF1 knockdown in RCC cells

To further investigate which genes and pathways are suppressed by miR-101/UHRF1 signaling, we performed genome wide gene expression analysis using knockdown of UHRF1 by siRNA in 786-O cells. We deposited these data in the GEO (accession number: GSE77790). Genes which were significantly downregulated by si-UHRF1 (Log2 [si-UHRF1/mock] < –1.0) were categorized by KEGG pathway analysis using the GeneCodis program. Table Table55 shows pathways that were significantly downregulated by knockdown of UHRF1. Pathways related to post-transcriptional modification, including the nucleotide excision repair and mismatch repair pathways, were significantly suppressed by knockdown of UHRF1.

Table 5
Significantly downregulated pathways by knockdown of UHRF1 in 786-O cells

UHRF1 and EZH2 expression in sunitinib-treated clinical RCC specimens

Finally, we examined UHRF1 expression status in clinical RCC specimens.

In a study with a relatively large sample size in GSE65615, higher UHRF1 expression was observed in sunitinib-treated RCC specimens compared with that in sunitinib-naïve RCC specimens (P = 0.0049; Figure Figure6A).6A). To examine whether UHRF1 expression predicted overall survival, we used the TCGA-KIRC database (https://tcga-data.nci.nih.gov/tcga/). A total of 533 patients who underwent surgery for RCC and were pathologically diagnosed as having clear cell RCC were divided into two groups: z-score > 0 and z-score < 0 [16, 17]. Higher expression of UHRF1 was associated with shorter overall survival (P < 0.0001; Figure Figure6B).6B). Multivariate Cox proportional hazards models were used to assess independent predictors of overall survival times, including disease stage, pT stage, age at diagnosis, gender, and UHRF1 expression. High UHRF1 expression was one of the significant prognostic factors in patients with RCC (hazard ratio = 2.027, 95% confidence interval = 1.490– 2.759, P < 0.0001; Figure Figure6C).6C). To analyze UHRF1 protein expression, immunohistochemistry was performed with sunitinib-treated specimens. Immunohistochemical staining of UHRF1 in these specimens demonstrated high expression of UHRF1 in sunitinib-treated RCC cells (Figure (Figure6D6D).

Figure 6
Clinical significance of UHRF1 expression in RCC

Similarly, we analyzed EZH2 status in clinical specimens. In GSE65615, we did not find significant difference of EZH2 expression between sunitinib-treated RCC specimens and sunitinib-naïve RCC specimens (Figure (Figure7A).7A). Higher expression of EZH2 was associated with shorter overall survival (P < 0.0001; Figure Figure7B).7B). High EZH2 expression was one of the significant prognostic factors in patients with RCC (hazard ratio = 1.828, 95% confidence interval = 1.348–2.493, P < 0.0001; Figure Figure7C).7C). High expression of EZH2 was observed in several sunitinib-treated RCC specimens (Figure (Figure7D7D).

Figure 7
Clinical significance of EZH2 expression in RCC

DISCUSSION

In patients treated with sunitinib, the initial response rate is approximately 40%; however, sunitinib-treated RCC cells usually acquire resistance to tyrosine kinase inhibitors [18]. Thus, overcoming sunitinib resistance is a major challenge for medical oncologists and urologists. Some mechanisms for sunitinib resistance in RCC have been described. One of the most well-studied pathways is hypoxia. VEGF-targeted drugs (e.g., sunitinib, pazopanib, axitinib, etc.) promote hypoxia in tumors by inhibiting angiogenesis, leading to high expression of HIF proteins [19]. Consequently, HIF proteins bind to hypoxia-responsive elements (HRE) and promote the expression of multiple oncogenes [20, 21]. Another mechanism is the activation of alternative signaling pathways. Hepatocyte growth factor (HGF)/cMET signaling, sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P)/extracellular signal-regulated kinase (ERK) signaling, and delta-like ligand4 (DLL4)/Notch signaling have significant roles in drug resistance [2224].

Our research group has sequentially identified novel RCC oncogenic pathways based on antitumor miRNAs identified using RCC miRNA signatures [11, 13, 25, 26]. Our miRNA-mediated RNA network analysis may provide many insights into RCC pathogenesis. In this study, we constructed a miRNA expression signature using autopsy specimens from patients with RCC who showed sunitinib failure. We believe that this miRNA signature will contribute to analysis of the mechanisms mediating resistance to sunitinib treatment. We identified 40 microRNAs that were downregulated in sunitinib-treated RCC tissues compared with that in untreated RCC tissues. Among these downregulated miRNAs, we identified miR-29b, which has been reported to suppress the extracellular matrix (ECM). In RCC cells, miR-29b directly suppresses the lysyl oxidase-like 2 (LOXL2) gene, leading to inhibition of cancer cell invasion [25]. Furthermore, miR-23b, miR- 10b,miR-135a, miR-29c, miR-27b, miR-1, and miR- 26b have been reported as tumour-suppressive miRNAs in RCC by different research groups [12, 2630]. In particular, let-7c sensitizes cells to 5-FU in RCC cells in vitro, and miR-27b sensitizes cells to doxorubicin, sorafenib, gefitinib in RCC cells [31, 32]. Chemoresistance and miRNAs listed in this signature have been reported previously in a variety of cancers: miR-29b in ovarian cancer, miR-128 in breast cancer, miR-23b in gastric cancer, and miR-10b in colorectal and breast cancer [3336]. Therefore, miRNAs listed in this signature would have importance in resistance to both chemotherapy and molecular targeted therapy. These facts ensure the reliability of the data in this signature.

In this study, we focused on the miR-101 because miR-101 was the most strongly downregulated miRNA in sunitinib-treated tissues. Our present data showed that miR-101 functioned as an antitumor miRNA in RCC cells. The antitumor roles of miR-101 have been reported in various types of cancers, including hepatocellular carcinoma, gastric cancer, breast cancer, and lung cancer [3740]. Furthermore, miR-101 restoration enhances chemosensitivity in lung cancer and salivary gland adenoid cystic carcinoma [41, 42]. Thus, our data are consistent with previous studies of miR-101 in cancer research.

One interesting capacity of miRNA analyses is identification of miRNA-regulated genes in the human genome and investigation of the functional roles of these miRNA-regulated genes in cancer cells. In this study, we found that UHRF1, the master regulator of epigenetic modifications, was directly suppressed by miR-101 in RCC cells and that its expression enhanced cancer cell migration and invasion. Moreover, overexpression of UHRF1 was confirmed in sunitinib-treated RCC tissues, and higher expression of UHRF1 was associated with shorter overall survival after surgery for RCC. Because sunitinib is the first-line treatment option for recurrent RCC after surgical treatment, this association is consistent with other results. Ablation of UHRF1 induces genomic hypomethylation, and overexpression of UHRF1 has been reported in several cancers [43, 44]. UHRF1 consists of five recognizable domains: PHD, Tudor, SRA, RING, and UBL [45]. UHRF1 is required for DNA methyltransferase 1 (DNMT1) function through direct binding to DNMT1 and activation of DNMT1 function for maintenance of DNA methylation [46].

We found that miR-101 directly suppressed UHRF1; however, previous reports have indicated that EZH2 is also directly suppressed by miR-101 [14, 47]. Consistent with this, we confirmed that EZH2 was suppressed by miR-101 in RCC cells (Figure (Figure4).4). Interestingly, EZH2 has also been reported to be a master regulator of transcription by modulation of histone modification or methylation [48, 49]. miR-101 can target and suppress both UHRF1 and EZH2 in RCC cells. Previous report indicated that UHRF1 and EZH2 synergistically and independently silence tumor suppressors by methylation: UHRF1 induce methylation of tumor suppressor gene DNA CpGs and H3-K9me3, and EZH2 induce methylation of H3-K27 [50]. Overexpression of both UHRF1 and EZH2 coordinately suppressed antitumor genes and contributed to prostate cancer pathogenesis and metastasis [50]. More recently, patient-derived clear cell RCC xenografts with sunitinib resistant phenotype showed increased EZH2 expression, and inhibition of EZH2 resulted in enhancement of the antitumor effects of sunitinib [51]. Consequently, we speculate that overexpression of UHRF1 and EZH2 coordinately suppressed antitumor genes and deeply contribute to sunitinib resistant processes in RCC cells. In sunitinib-treated RCC tissues, loss of antitumor miR- 101 may lead to upregulation of UHRF1 and EZH2, and consequently, post-transcriptional modification of multiple genes would promote cancer-related phenotypes in cells. Moreover, we investigated the downstream pathways suppressed by knockdown of UHRF1 and found that pathways such as cell cycle, DNA replication, and RNA degradation were enriched in RCC cells. Thus, antitumor miR-101-mediated UHRF1 pathways may be suppressed by sunitinib treatment. Our present data will contribute to our understanding of drug-resistance mechanisms in RCC cells.

MATERIALS AND METHODS

Patients and clinical RCC specimens

Clinical kidney specimens were obtained from patients admitted to Kagoshima University Hospital and Teikyo University Chiba Medical Centre Hospital from 2004 to 2014. A total of 42 pairs of clear cell renal carcinoma and adjacent noncancerous tissue were obtained by nephrectomy. Three patients who died of RCC after sunitinib treatment failure underwent autopsies. RCC tissues (n = 42), adjacent noncancerous kidney tissues (n = 41), and sunitinib-treated RCC tissues (n= 11) were used. The patients' backgrounds and characteristics are summarized in Tables Tables11 and and3.3. Samples were staged according to the UICC TNM classification. Written consent for tissue donation for research purposes was obtained from each patient before sample collection. The protocol was approved by the Institutional Review Board of Chiba University, Kagoshima University and Teikyo University.

Construction of the miRNA expression signature of sunitinib-treated RCC

miRNA expression patterns were evaluated using a TaqMan LDA Human microRNA Panel v2.0 (Applied Biosystems, Foster City, CA, USA). A cut-off P-value of less than 0.05 was used to narrow down the candidates after global normalization of the raw data. After global normalization, additional normalization was carried out with the U6 gene. The procedure was performed as described previously [11, 52].

Cell culture

Human RCC cell lines (786-O and Caki-1 cells) were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO2 and 95% air at 37°C.

RNA isolation

Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The quality of RNA was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies) as described previously [5254].

Quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR)

The expression levels of miR-101 (Assay ID: 002253) were analyzed by TaqMan RT-qPCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to RNU48 expression (Assay ID: 001006). TaqMan probes and primers for UHRF1(P/N: Hs01086727_m1), EZH2 (P/N: Hs01016789_m1), and GAPDH (P/N: Hs02758991_g1) as an internal control were obtained from Applied Biosystems (Assay-On-Demand Gene Expression Products). The procedure was carried out as previously described [52, 53].

Transfection with miRNA mimic and small-interfering RNA (siRNA)

Ambion Pre-miR miRNA precursor for hsa-miR-101-3p (product ID: PM11414) was used in this study as a miRNA mimic. The following siRNAs were used: Stealth Select RNAi siRNA; si-UHRF1 (cat no.: HSS179005 and HSS179006; Invitrogen); and negative control miRNA/siRNA (P/N: AM17110; Applied Biosystems). RNAs were incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMAX reagent (Invitrogen). The transfection procedures were performed as previously described [52, 53].

Cell proliferation, migration, and invasion assays

Cell proliferation assays were performed using XTT assays, migration assays were performed using uncoated Transwell polycarbonate membrane filters, and invasion assays were performed using Matrigel-coated Boyden chambers, as previously described [52, 53].

Identification of genes suppressed by miR-101

A combination of in silico and genome-wide gene expression analyses were carried out to investigate target genes suppressed by miR-101. First, genes suppressed by miR-101 were listed using the TargetScan database. Next, to identify upregulated genes in RCC, we analyzed a publicly available gene expression data set in the Gene Expression Omnibus (GEO; accession numbers: GSE36985 and GSE22541). Finally, upregulated mRNAs containing miR- 101 target sites were listed as putative target genes of miR-101. The procedure for selection is summarized in Figure Figure22.

Western blotting

Immunoblotting was performed with rabbit anti-UHRF1 antibodies (1:1000, PA5-29884; Pierce Antibodies, Thermo Scientific, Fremont, CA, USA) and anti-EZH2 antibodies (1:250, 36-6300; Life Technologies, Carlsbad, CA, USA). Anti-GAPDH antibodies (1:1000, ab8245; Abcam, Cambridge, UK) were used as an internal loading control. Membranes were washed and incubated with anti-rabbit IgG horseradish peroxidase (HRP)-linked antibodies (7074; Cell Signaling Technology, Danvers, MA, USA). Complexes were visualized with Clarity Western ECL Substrate (Bio-Rad, Hercules, CA, USA). The procedures were performed as previously described [52, 53].

Plasmid construction and dual-luciferase reporter assay

Partial wild-type sequences of the UHRF1 3′ untranslated region (UTR) or those with a deleted miR-101 target site (position 1030–1036 of the UHRF1 3′ UTR) were inserted between the XhoI–PmeI restriction sites in the 3′ UTR of the hRluc gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The protocol for vector construction was described previously [52, 53].

Identification of pathways and genes suppressed by UHRF1 in RCC

To identify molecular pathways suppressed by UHRF1 gene expression in RCC cells, we performed gene expression analysis using si-UHRF1-transfected 786-O cells. An oligomicroarray (SurePrint G3 Human 8×60k v3; Agilent Technologies) was used for gene expression studies. The data were deposited in the GEO database (accession number GSE77790). Genes downregulated by knockdown of UHRF1 were categorized into Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways using the GENECODIS program (http://genecodis.cnb.csic.es/). The strategy of this analysis procedure has been described previously [5254].

Immunohistochemisty

A total of 11 specimens were used (Table (Table1).1). Tissue specimens were immunostained with an Ultra-Vision Detection System (Thermo Scientific) following the manufacturer's protocol. Primary rabbit polyclonal antibodies against UHRF1 (1:500, PA5-29884; Pierce Antibodies, Thermo Scientific) and EZH2 (1:125, 36-6300; Life Technologies) were used for immunochemistry. The slides were treated with biotinylated goat antibodies (Histofine SAB-PO kit; Nichirei, Tokyo, Japan). The procedures were performed as previously described [5254].

TCGA-KIRC and other human RCC data analysis

To explore the clinical significance of UHRF1 in RCC, we used the RNA sequencing database in TCGA-KIRC (The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma: https://tcga-data.nci.nih.gov/tcga/). The gene expression and clinical data were retrieved from cBioportal (http://www.cbioportal.org/, the provisional data downloaded on May 10th, 2016). The normalized mRNA expression value in the RNA sequencing data was processed and provided in Z-score. We performed multivariate analysis (Cox proportional hazards model) that included pathological tumour and disease stage, age, and gender under consideration. We also employed the gene expression microarray data including sunitinib-treated and sunitinib-naïve human RCC specimens (GSE 65615).

Statistical analysis

The relationships between 2 groups and numerical values were analyzed using Mann-Whitney U-tests. The relationships among more than 3 variables and numerical values were analyzed using the Bonferroni-adjusted Mann-Whitney U-test. A multivariate Cox proportional hazards model was used to establish independent factors for overall survival. Survival analysis was carried out using the Kaplan–Meier method and log-rank tests. The Kaplan–Meier method and log-rank test were performed using JMP software (version 12, SAS Institute Inc., Cary, NC, USA); all other analyses were performed using Expert StatView (version 5, SAS Institute Inc.).

SUPPLEMENTARY MATERIALS TABLE

ACKNOWLEDGMENTS AND FUNDING

This study was supported by the KAKENHI, grant numbers (C) 15K10801, (C) 26462430, (B) 15K20071, (B) 25293333, and (B) 16H05462.

Footnotes

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi: 10.1002/ijc.29210. [PubMed] [Cross Ref]
2. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, et al. Kidney cancer, version 3. 2015. J Natl Compr Canc Netw. 2015;13:151–9. [PubMed]
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. doi: 10.1056/NEJMoa065044. [PubMed] [Cross Ref]
4. Tomita Y. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment. Int J Urol. 2016;23:13–21. doi: 10.1111/iju.12899. [PubMed] [Cross Ref]
5. Porta C, Paglino C, Grunwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer. 2014;111:1047–53. doi: 10.1038/bjc.2014.214. [PMC free article] [PubMed] [Cross Ref]
6. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93–113. doi: 10.1093/jnci/djr511. [PubMed] [Cross Ref]
7. Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. Functional significance of aberrantly expressed microRNAs in prostate cancer. Int J Urol. 2015;22:242–52. doi: 10.1111/iju.12700. [PubMed] [Cross Ref]
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33. doi: 10.1016/j.cell.2009.01.002. [PMC free article] [PubMed] [Cross Ref]
9. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009;60:167–79. doi: 10.1146/annurev.med.59.053006.104707. [PubMed] [Cross Ref]
10. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–52. doi: 10.1038/nature12986. [PMC free article] [PubMed] [Cross Ref]
11. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, Fuse M, Nakagawa M, Enokida H. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3:44–57. doi: 10.18632/oncotarget.417. [PMC free article] [PubMed] [Cross Ref]
12. Ishihara T, Seki N, Inoguchi S, Yoshino H, Tatarano S, Yamada Y, Itesako T, Goto Y, Nishikawa R, Nakagawa M, Enokida H. Expression of the tumor suppressive miRNA-23b/27b cluster is a good prognostic marker in clear cell renal cell carcinoma. J Urol. 2014;192:1822–30. doi: 10.1016/j.juro.2014.07.001. [PubMed] [Cross Ref]
13. Yoshino H, Enokida H, Itesako T, Kojima S, Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M, Seki N. Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci. 2013;104:1567–74. doi: 10.1111/cas.12280. [PubMed] [Cross Ref]
14. Sakurai T, Bilim VN, Ugolkov AV, Yuuki K, Tsukigi M, Motoyama T, Tomita Y. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells. Biochem Biophys Res Commun. 2012;422:607–14. doi: 10.1016/j.bbrc.2012.05.035. [PubMed] [Cross Ref]
15. Zheng M, Jiang YP, Chen W, Li KD, Liu X, Gao SY, Feng H, Wang SS, Jiang J, Ma XR, Cen X, Tang YJ, Chen Y, et al. Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma. Oncotarget. 2015;6:6797–810. doi: 10.18632/oncotarget.3180. [PubMed] [Cross Ref]
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi: 10.1126/scisignal.2004088. [PMC free article] [PubMed] [Cross Ref]
17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4. doi: 10.1158/2159-8290.CD-12-0095. [PMC free article] [PubMed] [Cross Ref]
18. Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al. Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. Eur Urol. 2016;69:4–6. doi: 10.1016/j.eururo.2015.10.017. [PubMed] [Cross Ref]
19. Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M, Tjan-Heijnen VC. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015;1855:1–16. doi: 10.1016/j.bbcan.2014.11.002. [PubMed] [Cross Ref]
20. Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47. doi: 10.1038/nrc704. [PubMed] [Cross Ref]
21. Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221:125–38. doi: 10.1002/path.2689. [PubMed] [Cross Ref]
22. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70:10090–100. doi: 10.1158/0008-5472.CAN-10-0489. [PubMed] [Cross Ref]
23. Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, et al. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res. 2015;21:1925–34. doi: 10.1158/1078-0432.CCR-14-2031. [PMC free article] [PubMed] [Cross Ref]
24. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Wu H, Chowdhury PS, Russell AJ, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011;71:6073–83. doi: 10.1158/0008-5472.CAN-11-1704. [PubMed] [Cross Ref]
25. Nishikawa R, Chiyomaru T, Enokida H, Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa M, Seki N. Tumour-suppressive microRNA-29s directly regulate LOXL2 expression and inhibit cancer cell migration and invasion in renal cell carcinoma. FEBS Lett. 2015;589:2136–45. doi: 10.1016/j.febslet.2015.06.005. [PubMed] [Cross Ref]
26. Kurozumi A, Kato M, Goto Y, Matsushita R, Nishikawa R, Okato A, Fukumoto I, Ichikawa T, Seki N. Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol. 2016;48:1837–46. doi: 10.3892/ijo.2016.3440. [PMC free article] [PubMed] [Cross Ref]
27. Liu W, Zabirnyk O, Wang H, Shiao YH, Nickerson ML, Khalil S, Anderson LM, Perantoni AO, Phang JM. miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene. 2010;29:4914–24. doi: 10.1038/onc.2010.237. [PMC free article] [PubMed] [Cross Ref]
28. Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlback B. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer. 2014;50:1758–65. doi: 10.1016/j.ejca.2014.03.281. [PubMed] [Cross Ref]
29. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N, Seki N, Nakagawa M. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer. 2012;48:827–36. doi: 10.1016/j.ejca.2011.06.030. [PubMed] [Cross Ref]
30. Yamada Y, Hidaka H, Seki N, Yoshino H, Yamasaki T, Itesako T, Nakagawa M, Enokida H. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci. 2013;104:304–12. doi: 10.1111/cas.12072. [PubMed] [Cross Ref]
31. Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z, Li C, Ren H, Li Y, He X, Shi X, Hui L. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res. 2015;25:477–95. doi: 10.1038/cr.2015.23. [PMC free article] [PubMed] [Cross Ref]
32. Peng J, Mo R, Ma J, Fan J. let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma. World J Surg Oncol. 2015;13:175. doi: 10.1186/s12957-015-0596-4. [PMC free article] [PubMed] [Cross Ref]
33. Dai F, Zhang Y, Chen Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol. 2014;45:1285–93. doi: 10.1016/j.humpath.2014.02.008. [PubMed] [Cross Ref]
34. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y, Song E. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 2011;17:7105–15. doi: 10.1158/1078-0432.CCR-11-0071. [PubMed] [Cross Ref]
35. An Y, Zhang Z, Shang Y, Jiang X, Dong J, Yu P, Nie Y, Zhao Q. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6:e1766. doi: 10.1038/cddis.2015.123. [PMC free article] [PubMed] [Cross Ref]
36. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol. 2012;19:3065–71. doi: 10.1245/s10434-012-2246-1. [PubMed] [Cross Ref]
37. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135–42. doi: 10.1158/0008-5472.CAN-08-2886. [PubMed] [Cross Ref]
38. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ, Ye ZY, Tao HQ. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer. 2010;46:2295–303. doi: 10.1016/j.ejca.2010.05.012. [PubMed] [Cross Ref]
39. Li JT, Jia LT, Liu NN, Zhu XS, Liu QQ, Wang XL, Yu F, Liu YL, Yang AG, Gao CF. MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7. Oncotarget. 2015;6:30818–30. doi: 10.18632/oncotarget.5067. [PMC free article] [PubMed] [Cross Ref]
40. Wang L, Zhang LF, Wu J, Xu SJ, Xu YY, Li D, Lou JT, Liu MF. IL-1beta-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis. Cancer Res. 2014;74:4720–30. doi: 10.1158/0008-5472.CAN-14-0960. [PubMed] [Cross Ref]
41. Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014;20:3849–61. doi: 10.1158/1078-0432.CCR-13-1916. [PMC free article] [PubMed] [Cross Ref]
42. Liu XY, Liu ZJ, He H, Zhang C, Wang YL. MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. Am J Cancer Res. 2015;5:3015–29. [PMC free article] [PubMed]
43. Unoki M, Brunet J, Mousli M. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol. 2009;78:1279–88. doi: 10.1016/j.bcp.2009.05.035. [PubMed] [Cross Ref]
44. Matsushita R, Yoshino H, Enokida H, Goto Y, Miyamoto K, Yonemori M, Inoguchi S, Nakagawa M, Seki N. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness. Oncotarget. 2016 doi: 10.18632/oncotarget.8668. [PMC free article] [PubMed] [Cross Ref]
45. Hu L, Li Z, Wang P, Lin Y, Xu Y. Crystal structure of PHD domain of UHRF1 and insights into recognition of unmodified histone H3 arginine residue 2. Cell Res. 2011;21:1374–8. doi: 10.1038/cr.2011.124. [PMC free article] [PubMed] [Cross Ref]
46. Bashtrykov P, Jankevicius G, Jurkowska RZ, Ragozin S, Jeltsch A. The UHRF1 protein stimulates the activity and specificity of the maintenance DNA methyltransferase DNMT1 by an allosteric mechanism. J Biol Chem. 2014;289:4106–15. doi: 10.1074/jbc.M113.528893. [PMC free article] [PubMed] [Cross Ref]
47. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695–9. doi: 10.1126/science.1165395. [PMC free article] [PubMed] [Cross Ref]
48. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128–34. doi: 10.1038/nm.4036. [PMC free article] [PubMed] [Cross Ref]
49. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17:2613–8. doi: 10.1158/1078-0432.CCR-10-2156. [PubMed] [Cross Ref]
50. Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene. 2012;31:4878–87. doi: 10.1038/onc.2011.641. [PubMed] [Cross Ref]
51. Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther. 2015;14:513–22. doi: 10.1158/1535-7163.MCT-14-0208. [PMC free article] [PubMed] [Cross Ref]
52. Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M, Naya Y, Ichikawa T, Seki N. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker. Br J Cancer. 2015;113:1055–65. doi: 10.1038/bjc.2015.300. [PMC free article] [PubMed] [Cross Ref]
53. Goto Y, Kojima S, Kurozumi A, Kato M, Okato A, Matsushita R, Ichikawa T, Seki N. Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer. Br J Cancer. 2016;114:1135–44. doi: 10.1038/bjc.2016.95. [PMC free article] [PubMed] [Cross Ref]
54. Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa T, Seki N. Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci. 2016;107:84–94. doi: 10.1111/cas.12842. [PMC free article] [PubMed] [Cross Ref]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC